内镜下经鼻蝶垂体手术后加速康复与提前出院:安全性、患者反馈及费用影响
该研究回顾性比较单一英国中心2016年7月至2019年11月连续收治的择期垂体腺瘤手术患者,方案改变前52例与加速康复(ERAS)方案后55例。ERAS组30天再入院率9%与方案前8%相似(p=0.75),平均住院日由4.5天降至1.7天、中位住院日由3天降至1天(p<0.05),ERAS组55例中39例术后第1天出院,患者满意度均分9.7/10。结论认为择期内镜下垂体手术加速康复方案安全、缩短住院日且患者满意度高。
要点
- ERAS组30天再入院率9%与方案前8%相似(p=0.75)。
- ERAS组平均住院日1.7天、中位1天,较方案前4.5天和3天显著缩短(p<0.05)。
- ERAS组55例中39例术后第1天出院,满意度均分9.7/10。
核心结论
- 择期内镜下垂体手术采用加速康复方案安全,可缩短住院日,并与高患者满意度相关。
研究设计与样本
- 回顾性评估单一英国中心2016年7月至2019年11月连续收治的择期垂体腺瘤手术患者两个连续队列。
- 方案改变前队列包括52例连续患者,ERAS队列包括55例连续患者。
- 记录患者人口学数据、肿瘤特征、术中及术后脑脊液漏、30天内再入院率及原因、平均和中位住院日。
- 从ERAS组部分患者(n=23)收集患者反馈。
主要发现
- 两个队列在人口学、病理和手术特征方面匹配良好。
- 出院后30天内再入院率两组相似:方案前队列8%,ERAS队列9%,p=0.75。
- 方案前队列平均住院日4.5天、中位3天;ERAS组平均1.7天、中位1天(p<0.05)。
- ERAS组55例中39例术后第1天出院。
- ERAS组患者反馈非常积极,Likert量表平均满意度评分9.7/10。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Enhanced recovery after surgery (ERAS) is a constant motivation. There is growing evidence that an endoscopic (rather than microscopic) transsphenoidal approach to pituitary tumours can play a role, facilitating faster recovery and a commensurate reduction in length of stay (LOS). Reducing LOS is beneficial to both patients and healthcare systems. We sought to assess the safety, patient feedback, and resource implications of adopting an enhanced recovery and accelerated discharge policy for elective pituitary surgery. METHODS: We retrospectively assessed two consecutive cohorts of patients undergoing elective surgery for pituitary adenoma in a single UK centre between July 2016 and November 2019. The pre-ERAS cohort included 52 sequential patients operated prior to protocol change. The ERAS cohort included 55 sequential patients operated after a protocol change. Patient demographic data, tumour characteristics, intra- and post-operative CSF leak, the rate and cause of readmission (within 30 days), and the mean and median LOS were recorded. Patient feedback was collected from a subset of patients (n = 23) in the ERAS group. RESULTS: The two cohorts were well-matched with respect to their demographic, pathological, and operative characteristics. The rates of readmission within 30 days of discharge were similar between the two groups (8% pre-ERAS cohort, 9% ERAS cohort, p = 0.75). In the pre-ERAS cohort, the mean LOS was 4.5 days and median LOS was 3 days. This compares with significant reduction in LOS for the ERAS group: mean of 1.7 days and median of 1 day (p < 0.05). Thirty-nine of 55 patients in the ERAS group were discharged on post-operative day 1. Patient feedback was very positive in the ERAS group (mean patient satisfaction score of 9.7/10 using a Likert scale). CONCLUSIONS: An enhanced recovery protocol after elective endoscopic pituitary surgery is safe, reduces length of stay, and is associated with high patient satisfaction.
引用
- Hughes MA, Culpin E, Darley R, et al. Enhanced recovery and accelerated discharge after endoscopic transsphenoidal pituitary surgery: safety, patient feedback, and cost implications. Acta Neurochir (Wien). 2020. PMID: 32144485. doi:10.1007/s00701-020-04282-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。